Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total revenue. Contemporaneous with the spinoff in June 2013 S&P Dow Jones Indices announced that Zoetis would replace First Horizon National Corporation in the S&P 500 stock market index.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| ZTS | Zoetis Inc. | 2025-10-30 19:48:57 | 142.3 | -1.8 | -1.25 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZTS | 0001555280 | Zoetis Inc. | US98978V1035 | 549300HD9Q1LOC9KLJ48 | 460696167 | NYSE | 2834 | Pharmaceutical Preparations | 1231 | — | 10 SYLVAN WAY | PARSIPPANY | NJ | 07054 | UNITED STATES | US | 973-822-7000 | 10 SYLVAN WAY, PARSIPPANY, NJ, 07054 | 10 SYLVAN WAY, PARSIPPANY, NJ, 07054 | — | Pharmaceutical | 1952 | Kristin Peck | 13,800 | http://zoetis.com | 78,673,000,000 | 501,891,243 | 443,183,472 | Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total revenue. Contemporaneous with the spinoff in June 2013 S&P Dow Jones Indices announced that Zoetis would replace First Horizon National Corporation in the S&P 500 stock market index. | 2025-10-30 12:16:13 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 78,673,000,000 | -673,000,000 | -0.8482 | 447,791,917 | -10,075,198 | -2.2005 |
| 2023 | 79,346,000,000 | -1,204,000,000 | -1.4947 | 457,867,115 | -5,519,601 | -1.1911 |
| 2022 | 80,550,000,000 | -7,824,000,000 | -8.8533 | 463,386,716 | -8,583,864 | -1.8187 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Kristin C. Peck | Chief Executive Officer | 2021 | 1,200,000 | 0 | 6,929,797 | 2,340,000 | 318,724 | 13,098,491 |
| Catherine A. Knupp | EVP, President | 2021 | 710,000 | 0 | 1,368,661 | 852,000 | 168,376 | 3,555,260 |
| Roman Trawicki | EVP, President | 2021 | 675,000 | 0 | 1,049,922 | 842,400 | 401,419 | 3,318,727 |
| Heidi C. Chen | EVP, Corporate Secretary, General Counsel | 2021 | 615,000 | 0 | 993,543 | 645,750 | 133,861 | 2,719,382 |
| Catherine A. Knupp | EVP, President | 2020 | 710,000 | 0 | 1,349,924 | 658,880 | 137,097 | 3,305,884 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 13,800 |
| 2023 | 14,100 |
| 2022 | 13,800 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 9,256,000,000 | 8,544,000,000 | 8,080,000,000 |
| Cost Of Revenue | 2,719,000,000 | 2,561,000,000 | 2,454,000,000 |
| Gross Profit | 4,138,000,000 | 3,655,000,000 | 3,510,000,000 |
| Research And Development Expenses | 686,000,000 | 614,000,000 | 539,000,000 |
| General And Administrative Expenses | 2,318,000,000 | 2,151,000,000 | 2,009,000,000 |
| Operating Expenses | 805,000,000 | 786,000,000 | 765,000,000 |
| Operating Income | — | — | — |
| Net Income | 2,486,000,000 | 2,344,000,000 | 2,114,000,000 |
| Earnings Per Share Basic | 5.47 | 5.08 | 4.51 |
| Earnings Per Share Diluted | 5.47 | 5.07 | 4.49 |
| Weighted Average Shares Outstanding Basic | 454,200,000 | 461,172,000 | 468,891,000 |
| Weighted Average Shares Outstanding Diluted | 454,848,000 | 462,269,000 | 470,385,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 1,987,000,000 | 2,041,000,000 | 3,581,000,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | 1,316,000,000 | 1,304,000,000 | 1,215,000,000 |
| Inventories | 2,306,000,000 | 2,564,000,000 | 2,345,000,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 377,000,000 | 434,000,000 | 365,000,000 |
| Total Assets Current | 5,986,000,000 | 6,343,000,000 | 7,506,000,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 3,391,000,000 | 3,204,000,000 | 2,753,000,000 |
| Other Assets Non Current | 250,000,000 | 206,000,000 | 147,000,000 |
| Total Assets Non Current | 8,251,000,000 | 7,943,000,000 | 7,419,000,000 |
| Total Assets | 14,237,000,000 | 14,286,000,000 | 14,925,000,000 |
| Accounts Payable | 433,000,000 | 411,000,000 | 405,000,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 0 | 3,000,000 | 2,000,000 |
| Other Liabilities Current | 125,000,000 | 102,000,000 | 97,000,000 |
| Total Liabilities Current | 3,412,000,000 | 1,889,000,000 | 3,167,000,000 |
| Long Term Debt | 5,220,000,000 | 6,564,000,000 | 6,552,000,000 |
| Other Liabilities Non Current | 222,000,000 | 237,000,000 | 217,000,000 |
| Total Liabilities Non Current | 6,055,000,000 | 7,406,000,000 | 7,355,000,000 |
| Total Liabilities | 9,467,000,000 | 9,295,000,000 | 10,522,000,000 |
| Common Stock | 5,000,000 | 5,000,000 | 5,000,000 |
| Retained Earnings | 11,968,000,000 | 10,295,000,000 | 8,668,000,000 |
| Accumulated Other Comprehensive Income | -940,000,000 | -839,000,000 | -817,000,000 |
| Total Shareholders Equity | 4,770,000,000 | 4,997,000,000 | 4,405,000,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 497,000,000 | 491,000,000 | 465,000,000 |
| Share Based Compensation Expense | 74,000,000 | 60,000,000 | 62,000,000 |
| Other Non Cash Income Expense | 6,000,000 | 8,000,000 | -13,000,000 |
| Change In Accounts Receivable | 61,000,000 | 102,000,000 | 137,000,000 |
| Change In Inventories | 40,000,000 | 361,000,000 | 486,000,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | -52,000,000 | 95,000,000 | -35,000,000 |
| Change In Accounts Payable | 31,000,000 | 13,000,000 | -29,000,000 |
| Change In Other Liabilities | 114,000,000 | 67,000,000 | -180,000,000 |
| Cash From Operating Activities | 2,953,000,000 | 2,353,000,000 | 1,912,000,000 |
| Purchases Of Marketable Securities | 5,000,000 | 4,000,000 | 9,000,000 |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 655,000,000 | 732,000,000 | 586,000,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | 3,000,000 | -2,000,000 | 0 |
| Cash From Investing Activities | -315,000,000 | -777,000,000 | -883,000,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | 812,000,000 | 716,000,000 | 631,000,000 |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | 1,858,000,000 | 1,092,000,000 | 1,594,000,000 |
| Issuance Of Long Term Debt | 0 | 0 | 1,348,000,000 |
| Repayment Of Long Term Debt | 0 | 1,350,000,000 | 0 |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -2,660,000,000 | -3,109,000,000 | -904,000,000 |
| Change In Cash | -54,000,000 | -1,540,000,000 | 96,000,000 |
| Cash At End Of Period | 1,987,000,000 | 2,041,000,000 | 3,581,000,000 |
| Income Taxes Paid | 892,000,000 | 754,000,000 | 638,000,000 |
| Interest Paid | 274,000,000 | 295,000,000 | 242,000,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | 5.47 | 5.08 | 4.51 |
| Price To Earnings Ratio | 29.7861 | 38.8524 | 32.4945 |
| Earnings Growth Rate | 7.6772 | 12.6386 | 5.1282 |
| Price Earnings To Growth Ratio | 3.8798 | 3.0741 | 6.3364 |
| Book Value Per Share | 10.502 | 10.8224 | 9.3902 |
| Price To Book Ratio | 15.5142 | 18.2371 | 15.6066 |
| Ebitda | 4,100,000,000 | 3,828,000,000 | 3,438,000,000 |
| Enterprise Value | 77,235,806,000 | 95,547,517,640 | 71,688,976,050 |
| Dividend Yield | 0.011 | 0.0079 | 0.0092 |
| Dividend Payout Ratio | 0.3266 | 0.3055 | 0.2985 |
| Debt To Equity Ratio | 1.0943 | 1.3142 | 1.4879 |
| Capital Expenditures | 684,000,000 | 942,000,000 | 796,000,000 |
| Free Cash Flow | 2,269,000,000 | 1,411,000,000 | 1,116,000,000 |
| Return On Equity | 0.5212 | 0.4691 | 0.4799 |
| One Year Beta | 0.6237 | 1.0077 | 0.9718 |
| Three Year Beta | 0.9172 | 0.9525 | 0.9398 |
| Five Year Beta | 0.9215 | 0.9436 | 0.9488 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Driscoll Rimma | Executive Vice President | 2025-10-10 | 149 | A | 5,226 |
| Sarbaugh Keith | Executive Vice President | 2025-10-10 | 158 | A | 1,098 |
| PECK KRISTIN C | Director, Chief Executive Officer | 2025-10-10 | 389 | A | 58,043 |
| Lagano Roxanne | Executive Vice President | 2025-10-10 | 201 | A | 28,624 |
| Joseph Wetteny | Chief Financial Officer | 2025-10-10 | 230 | A | 6,585 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Markwayne Mullin | Senator | 2025-08-12 | Purchase | 2024-01-04 | Spouse | $1,001 - $15,000 |
| Markwayne Mullin | Senator | 2025-08-12 | Purchase | 2024-01-04 | Self | $1,001 - $15,000 |
| Markwayne Mullin | Senator | 2025-06-11 | Purchase | 2025-05-13 | Joint | $50,001 - $100,000 |
| Markwayne Mullin | Senator | 2025-05-12 | Sale (Full) | 2025-04-08 | Joint | $15,001 - $50,000 |
| Markwayne Mullin | Senator | 2024-05-02 | Sale (Partial) | 2024-04-03 | Self | $1,001 - $15,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Rick Larsen | 2025-10-16 | WA02 | Sale | 2025-10-06 | — | $1,001 - $15,000 |
| Gilbert Cisneros | 2025-09-12 | CA31 | Sale (Partial) | 2025-08-05 | — | $1,001 - $15,000 |
| Lisa McClain | 2025-09-12 | MI09 | Sale | 2025-08-04 | Spouse | $1,001 - $15,000 |
| Lisa McClain | 2025-08-13 | MI09 | Purchase | 2024-12-11 | Spouse | $1,001 - $15,000 |
| Lisa McClain | 2025-08-13 | MI09 | Sale | 2025-01-15 | Spouse | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Aviance Capital Partners, LLC | 2025-09-30 | 4,486,264 | 30,661 | 146.3183 |
| Maryland State Retirement & Pension System | 2025-09-30 | 3,213,334 | 21,961 | 146.32 |
| Sequoia Financial Advisors, LLC | 2025-09-30 | 3,326,900 | 22,737 | 146.321 |
| Baer Investment Advisory LLC | 2025-09-30 | 2,983,611 | 20,391 | 146.32 |
| McBroom & Associates, LLC | 2025-09-30 | 4,222,087 | 28,855 | 146.3208 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Meeder Funds | 2025-09-30 | Adviser Class | SRUAX | 3,581 | 523,971.92 | 0.214 |
| Meeder Funds | 2025-09-30 | Institutional Class | SRUIX | 3,581 | 523,971.92 | 0.214 |
| Meeder Funds | 2025-09-30 | Retail Class | FLSPX | 3,581 | 523,971.92 | 0.214 |
| SHELTON FUNDS | 2025-08-31 | K Shares | SPXKX | 2,412 | 377,236.8 | 0.1256 |
| SHELTON FUNDS | 2025-08-31 | Investor Shares | SPFIX | 2,412 | 377,236.8 | 0.1256 |